Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 4Recruiting 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Neoplasms 3Gastrointestinal Stromal Tumors 3Carcinoma, Renal Cell 3Osteosarcoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Adenoma, Islet Cell 2Solid Tumors Refractory to Standard Therapy 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3Everolimus 3lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2sargramostim 1montanide ISA 51 1lanreotide 1incomplete Freund's adjuvant 1fludarabine phosphate 1belzutifan 1Sorafenib 1Radiofrequency Ablation 1Octreotide 1Interleukin-13 1Histocompatibility Testing 1Gefitinib 1Fulvestrant 1Fluorodeoxyglucose F18 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Colony-Stimulating Factors 1Capecitabine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Adenoma, Islet Cell × Sunitinib × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡